Sigyn Therapeutics CFO Gerald DeCiccio Retires; CEO James Joyce Appointed Interim CFO

Sigyn Therapeutics, Inc.

CFO Gerald DeCiccio retired effective February 26, 2025, with no disagreement with the company.
CEO James Joyce will serve as interim CFO following DeCiccio's retirement.
Sigyn entered into a Consulting Agreement with DeCiccio for continued financial support services.
CEO released a letter on March 5, 2025, outlining Sigyn Therapy's potential against emerging viral threats.
Sigyn Therapy targets viruses, bacterial toxins, inflammatory cytokines, and has a clinical strategy for ESRD patients.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

James Joyce

interim Chief Financial Officer

SIGY · Sigyn Therapeutics, Inc.

Effective: 2025-02-26
Filed: March 7, 2025, 6:59 PM ET

Mr. James Joyce, our Chief Executive Officer, will serve as our interim Chief Financial Officer.

Departed

Gerald DeCiccio

Chief Financial Officer

SIGY · Sigyn Therapeutics, Inc.

Effective: 2025-02-26
Successor: James Joyce
Filed: March 7, 2025, 6:59 PM ET

On February 26, 2025, our Chief Financial Officer, Mr. Gerald DeCiccio provided us a notice of retirement, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

James Joyce was appointed as interim Chief Financial Officer at Sigyn Therapeutics, Inc..

Action: appointed
Role: interim Chief Financial Officer

Exact text from the filing

Mr. James Joyce, our Chief Executive Officer, will serve as our interim Chief Financial Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Gerald DeCiccio retired as Chief Financial Officer at Sigyn Therapeutics, Inc..

Action: retired
Role: Chief Financial Officer

Exact text from the filing

On February 26, 2025, our Chief Financial Officer, Mr. Gerald DeCiccio provided us a notice of retirement, effective immediately.

View on SEC.gov

Sigyn Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-009462

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.